



Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

Naruto Taira¹ · Kosuke Kashiwabara² · Junji Tsurutani³ · Masahiro Kitada⁴ · Masato Takahashi⁵ · Hiroaki Kato⁶ · Yuichiro Kikawa⁷ · Eiko Sakata⁸ · Yoichi Naito⁹ · Yoshie Hasegawa¹⁰ · Tsuyoshi Saito¹¹ · Tsutomu Iwasa¹² · Tsutomu Takashima¹³ · Tomohiko Aihara¹⁴ · Hirofumi Mukai⁹ · Fumikata Hara¹⁵

Published online: 25 September 2021
© The Japanese Breast Cancer Society 2021

Correction to: Breast Cancer
<https://doi.org/10.1007/s12282-021-01290-5>

In the original publication of the article, the Table 2 was published incorrectly with missing values. The corrected Table 2 is given in this correction.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s12282-021-01290-5>.

✉ Naruto Taira
ntaira@md.okayama-u.ac.jp

¹ Department of Breast and Endocrine Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

² Clinical Research Promotion Center, University of Tokyo Hospital, Tokyo, Japan

³ Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan

⁴ Breast Disease Center, Asahikawa Medical University Hospital, Hokkaido, Japan

⁵ Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan

⁶ Department of Breast Surgery, Teine Keijinkai Hospital, Hokkaido, Japan

⁷ Department of Breast Surgery, Kansai Medical University Hospital, Osaka, Japan

⁸ Department of Breast Surgery, Niigata City General Hospital, Niigata, Japan

⁹ Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan

¹⁰ Department of Breast Surgery, Hirosaki Municipal Hospital, Aomori, Japan

¹¹ Department of Breast Surgery, Japanese Red Cross Saitama Hospital, Saitama, Japan

¹² Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan

¹³ Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan

¹⁴ Breast Center, Aihara Hospital, Osaka, Japan

¹⁵ Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Table 2 Mean scores at each survey point

Questionnaire	Survey point	Treatment group						P value*
		Number of responses, mean score (SD)						
		SD 260		MD 220		LD 180		
		(n = 44)		(n = 45)		(n = 47)		
FACT-Taxane								
Taxane total	Baseline	44	124.7 (19.8)	44	121.6 (18.4)	47	122.8 (20.6)	0.75
	2nd course	42	111.4 (21.0)	42	117.4 (22.3)	42	121.1 (20.6)	
	4th course	34	104.4 (22.8)	36	115.6 (20.9)	37	119.3 (20.8)	
	6th course	28	106.6 (23.1)	30	117.5 (19.8)	31	117.2 (24.0)	
General total	Baseline	43	68.7 (15.9)	44	67.0 (13.6)	47	67.5 (15.9)	0.86
	2nd course	42	64.7 (15.4)	42	66.5 (15.0)	42	67.3 (15.1)	
	4th course	34	62.1 (13.6)	36	66.5 (13.9)	37	69.5 (13.7)	
	6th course	28	64.8 (13.3)	30	68.4 (15.0)	31	69.2 (15.6)	
Taxane TOI	Baseline	44	93.4 (14.6)	44	90.6 (15.19)	47	91.4 (15.7)	0.68
	2nd course	42	79.4 (17.7)	42	86.2 (18.9)	42	89.4 (16.4)	
	4th course	34	73.3 (19.3)	36	83.7 (17.7)	37	86.9 (17.6)	
	6th course	29	72.3 (22.4)	30	85.2 (16.0)	31	84.6 (18.3)	
PWB	Baseline	44	20.2 (4.9)	44	19.3 (5.4)	47	18.6 (6.4)	0.38
	2nd course	42	18.2 (5.2)	43	20.0 (5.8)	42	18.6 (5.7)	
	4th course	35	16.5 (4.9)	36	19.4 (5.9)	37	19.8 (5.3)	
	6th course	29	16.4 (5.7)	30	19.6 (5.3)	31	19.1 (6.1)	
SFWB	Baseline	44	16.4 (6.2)	44	18.9 (5.4)	47	18.29 (6.1)	0.13
	2nd course	42	16.2 (6.1)	42	17.0 (6.3)	42	17.4 (6.1)	
	4th course	35	15.5 (6.1)	36	16.4 (6.0)	37	16.3 (6.6)	
	6th course	28	16.3 (5.2)	30	16.9 (6.7)	31	16.9 (6.1)	
EWB	Baseline	44	14.9 (5.6)	45	12.0 (5.0)	47	13.1 (6.0)	0.05
	2nd course	42	15.8 (5.0)	42	14.2 (5.6)	42	14.3 (4.7)	
	4th course	34	15.6 (4.7)	36	15.44 (5.0)	37	16.2 (4.6)	
	6th course	29	15.9 (5.0)	30	15.4 (5.1)	31	15.7 (4.4)	
FWB	Baseline	44	16.7 (6.8)	45	16.70 (5.1)	47	17.5 (5.4)	0.74
	2nd course	42	14.5 (6.7)	42	15.5 (5.9)	42	17.0 (6.2)	
	4th course	34	14.5 (5.76)	36	15.3 (5.2)	37	17.3 (5.4)	
	6th course	29	15.0 (5.9)	30	16.5 (6.1)	31	17.5 (5.3)	
Taxane subscale	Baseline	44	56.5 (7.3)	45	54.4 (9.0)	47	55.3 (8.2)	0.47
	2nd course	42	46.7 (10.2)	43	51.1 (10.4)	42	53.9 (9.5)	
	4th course	34	42.3 (12.3)	36	49.1 (10.0)	37	49.8 (10.9)	
	6th course	29	40.8 (13.6)	30	49.1 (8.5)	31	48.0 (10.2)	
EQ-5D Utility								
	Baseline	44	0.75 (0.17)	45	0.74 (0.17)	46	0.69 (0.15)	0.24
	2nd course	42	0.67 (0.15)	43	0.76 (0.18)	42	0.72 (0.17)	
	4th course	34	0.64 (0.15)	36	0.73 (0.18)	37	0.72 (0.17)	
	6th course	29	0.67 (0.15)	30	0.72 (0.16)	31	0.72 (0.16)	
CFS								
Total	Baseline	43	28.4 (6.2)	44	28.1 (5.3)	46	28.7 (6.2)	0.89
	2nd course	42	31.5 (8.0)	43	29.7 (5.6)	42	28.7 (5.9)	
	4th course	34	30.4 (5.6)	36	28.6 (5.3)	37	28.1 (5.5)	
	6th course	29	31.4 (6.3)	30	29.5 (5.2)	31	28.7 (6.6)	
Physical	Baseline	43	6.8 (5.4)	44	6.2 (4.5)	46	8.1 (5.9)	0.19
	2nd course	42	9.0 (6.6)	43	7.6 (5.3)	42	8.6 (6.0)	
	4th course	34	9.2 (5.9)	36	7.8 (4.6)	37	7.9 (5.8)	

Table 2 (continued)

Questionnaire	Survey point	Treatment group						P value*
		Number of responses, mean score (SD)						
		SD 260 (n = 44)		MD 220 (n = 45)		LD 180 (n = 47)		
Affective	6th course	29	10.2 (6.3)	30	8.1 (5.1)	31	8.6 (5.6)	0.86
	Baseline	43	8.7 (3.1)	44	8.6 (3.1)	46	8.3 (3.7)	
	2nd course	42	9.2 (3.3)	43	8.9 (2.8)	42	8.0 (3.9)	
	4th course	34	9.0 (2.3)	36	8.4 (3.4)	37	8.1 (3.6)	
Cognitive	6th course	29	8.9 (2.5)	30	9.0 (2.9)	31	8.1 (3.5)	0.14
	Baseline	43	13.0 (2.7)	44	13.3 (2.2)	46	12.2 (2.9)	
	2nd course	42	13.3 (2.3)	43	13.2 (2.6)	42	12.1 (3.8)	
	4th course	34	12.2 (3.3)	36	12.5 (3.1)	37	12.1 (3.6)	
	6th course	29	12.4 (3.6)	30	12.3 (3.3)	31	12.0 (3.2)	

SD standard deviation, SD 260 260 mg/m² of 3-week cycle nab-paclitaxel, MD 220 220 mg/m² of 3-week cycle nab-paclitaxel, LD 180 180 mg/m² of 3-week cycle nab-paclitaxel, *FACT-Taxane* Functional Assessment of Cancer Therapy-Taxane, *Taxane TOI* Taxane trial outcome index, *PWB* physical well-being, *SFWB* social and family well-being, *EWB* emotional well-being, *FWB* functional well-being, *EQ-5D* EuroQol 5-dimension, *CFS* Cancer Fatigue Scale.

*Baseline scores were compared by *t* test

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.